<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433898</url>
  </required_header>
  <id_info>
    <org_study_id>1381-0004</org_study_id>
    <nct_id>NCT03433898</nct_id>
  </id_info>
  <brief_title>This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer</brief_title>
  <official_title>An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the BI 754091 monotherapy dose-finding part (Part I) of the trial are&#xD;
      to investigate the following items in advanced solid tumours:&#xD;
&#xD;
        -  Safety, tolerability, and pharmacokinetics (PK) of BI 754091 as monotherapy.&#xD;
&#xD;
        -  Maximum tolerated dose (MTD) and/or recommended dose (RD) of BI 754091 monotherapy.&#xD;
&#xD;
      The main objectives of the Combination dose-finding part (Part II) of the trial are to&#xD;
      investigate the following items in advanced solid tumours:&#xD;
&#xD;
        -  Safety, tolerability, and PK of the combination treatment of BI 754091 and BI 754111.&#xD;
&#xD;
        -  MTD and/or RD of the combination treatment of BI 754091 and BI 754111.&#xD;
&#xD;
      The main objectives of the expansion part (Part III) of the trial are:&#xD;
&#xD;
        -  To further investigate the safety, tolerability, and PK of the RD of BI 754091 and BI&#xD;
           754111 combination in patients with gastric/esophagogastric junction cancer, esophageal&#xD;
           cancer, hepatocellular cancer or non-small cell lung cancer (NSCLC)&#xD;
&#xD;
        -  To explore the efficacy of the RD of the combination of BI 754091 and BI 754111 in&#xD;
           patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular&#xD;
           cancer or NSCLC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">November 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Maximum tolerated dose (MTD) of BI 754091</measure>
    <time_frame>Up to 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Number of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period (first cycle of treatment)</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: MTD of the BI 754091 plus BI 754111 combination</measure>
    <time_frame>Up to 9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment)</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part III: Objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Cmax: maximum measured concentration of BI 754091 in plasma</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: AUC0-504: area under the concentration-time curve of BI 754091 in plasma</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Cmax: maximum measured concentration of BI 754091 and BI 754111 in plasma</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: AUC0-504: area under the concentration-time curve of BI 754091 and BI 754111 in plasma</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Duration of response</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Defined as the duration from the date of first documented PR or CR according to RECIST Version 1.1 as assessed by the Investigator to the date of progressive disease (PD) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Disease control</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>CR, PR, or stable disease (SD) according to RECIST Version 1.1 as assessed by the Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I - Objective response (OR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II - Objective response (OR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754091</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754111</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Of full age (according to local legislation) at the time of signing of the informed&#xD;
             consent form (ICF)&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP)1 with negative serum pregnancy test at&#xD;
             screening and men able to father a child, who agree to use highly effective methods of&#xD;
             birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per&#xD;
             year when used consistently and correctly. A list of contraception methods meeting&#xD;
             these criteria is provided in the patient information. The requirement of&#xD;
             contraception does not apply to women of no childbearing potential but they must have&#xD;
             an evidence of such at screening&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial&#xD;
&#xD;
          -  Patients with measurable lesions according to RECIST v1.1&#xD;
&#xD;
          -  Conditions specific to respective part of the trial:&#xD;
&#xD;
               -  Part I (BI 754091 dose-finding part):&#xD;
&#xD;
                    -  Patients with a confirmed diagnosis of advanced, unresectable, and/or&#xD;
                       metastatic solid tumours (any type)&#xD;
&#xD;
                    -  For whom no therapy of proven efficacy exists, or who are not amenable to&#xD;
                       standard therapies.&#xD;
&#xD;
                    -  Previous treatment with an anti-PD-1 mAb is allowed as long as the last&#xD;
                       administration of the anti PD-1 mAb on the previous treatment is a minimum&#xD;
                       of 28 days prior to the first BI 754091 treatment.&#xD;
&#xD;
               -  Part II (Combination dose-finding part):&#xD;
&#xD;
                    -  Patients with a confirmed diagnosis of advanced, unresectable, and/or&#xD;
                       metastatic solid tumours (any type)&#xD;
&#xD;
                    -  For whom no therapy of proven efficacy exists, or who are not amenable to&#xD;
                       standard therapies.&#xD;
&#xD;
                    -  Previous treatment with an anti-PD-1 mAb is allowed as long as the last&#xD;
                       administration of the anti PD-1 mAb on the previous treatment is a minimum&#xD;
                       of 28 days prior to the first BI 754091 treatment.&#xD;
&#xD;
               -  Part III (Expansion part):&#xD;
&#xD;
                    -  Cohort A: Patients with gastric/esophagogastric junction cancer, with no&#xD;
                       prior treatment with anti-PD-1/PD-L1 antibody, and who received at least one&#xD;
                       line of systemic medical treatment excluding adjuvant therapy&#xD;
&#xD;
                    -  Cohort B: Patients with esophageal cancer with no prior treatment with&#xD;
                       anti-PD-1/PD-L1 antibody, and who received at least one line of systemic&#xD;
                       medical treatment excluding adjuvant therapy&#xD;
&#xD;
                    -  Cohort C: Patients with hepatocellular cancer with no prior treatment with&#xD;
                       anti-PD-1/PD-L1 antibody, who received at least one line of systemic medical&#xD;
                       treatment excluding adjuvant therapy, and whose Child-Pugh score is 7 or&#xD;
                       less&#xD;
&#xD;
                    -  Cohort D: Patients with gastric/esophagogastric junction cancer, esophageal&#xD;
                       cancer, or hepatocellular cancer with a prior treatment with anti-PD-1/PD-L1&#xD;
                       antibody&#xD;
&#xD;
                    -  Cohort E: First line squamous or non-squamous NSCLC patients:&#xD;
&#xD;
                         -  Without EGFR mutations or ALK rearrangements&#xD;
&#xD;
                         -  PD-L1 expression level &lt;50%&#xD;
&#xD;
                    -  All cohorts: Patients with advanced and/or metastatic disease, with at least&#xD;
                       1 tumour lesion amenable to biopsy, and must be medically fit for biopsy at&#xD;
                       screening as determined by investigator and willing to undergo a biopsy&#xD;
                       before first treatment (if adequate archival tissue is not available) and,&#xD;
                       unless clinically contraindicated, after 6 weeks on therapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0 to 1 at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery (major according to the investigator's assessment) performed within 12&#xD;
             weeks prior to study entry or planned within 12 months after screening, e.g. hip&#xD;
             replacement&#xD;
&#xD;
          -  Patients who must or wish to continue the intake of restricted medications or any drug&#xD;
             considered likely to interfere with the safe conduct of the trial&#xD;
&#xD;
          -  Previous treatment with study medications in this trial&#xD;
&#xD;
          -  Any investigational or anti-tumour treatment within 4 weeks or 5 half-life periods&#xD;
             (whichever is shorter) prior to the initiation of trial treatment&#xD;
&#xD;
          -  Any unresolved toxicities from prior therapy greater than Common Terminology Criteria&#xD;
             for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the&#xD;
             exception of alopecia and Grade 2 neuropathy due to prior platinum-based therapy&#xD;
&#xD;
          -  (Part II and III only) Prior treatment with anti-LAG-3 agents&#xD;
&#xD;
          -  Patients with lung cancer that have epidermal growth factor receptor (EGFR) mutations&#xD;
             or anaplastic lymphoma kinase (ALK) rearrangements, unless disease has progressed&#xD;
             following available EGFR or ALK targeted therapy&#xD;
&#xD;
          -  Presence of other active invasive cancers other than the one treated in this Trial&#xD;
             within 5 years Prior to screening, with the exception of appropriately treated basal&#xD;
             or squamous-cell carcinoma of the skin or in situ carcinoma of the uterine cervix, or&#xD;
             other local tumours considered cured by local treatment&#xD;
&#xD;
          -  Untreated brain metastasis(es) that may be considered active. Patients with previously&#xD;
             treated brain metastases may participate provided they are stable (i.e., without&#xD;
             evidence of PD by imaging for at least 4 weeks prior to the first dose of trial&#xD;
             treatment, and any neurologic symptoms have returned to baseline), and there is no&#xD;
             evidence of new or enlarging brain metastases&#xD;
&#xD;
          -  Inadequate organ function or bone marrow reserve as demonstrated by the following&#xD;
             laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1.5 x 10^9/L (&lt;1500/mm^3)&#xD;
&#xD;
               -  Platelet count &lt;100 x 10^9/L (&lt;100,000/mm^3)&#xD;
&#xD;
               -  Haemoglobin &lt;9.0 g/dL&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt;2.5 times the upper limit of normal (ULN) if no&#xD;
                  demonstrable liver lesion(s) (primary or metastases) or &gt;5 times ULN in the&#xD;
                  presence of liver lesion(s)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt;2.5 times ULN if no demonstrable liver&#xD;
                  lesion(s) or &gt;5 times ULN in the presence of liver lesion(s)&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 times ULN, except for patients with Gilbert's syndrome who&#xD;
                  are excluded if total bilirubin &gt;3.0 times ULN or direct bilirubin &gt;1.5 times ULN&#xD;
&#xD;
               -  Serum creatinine (measured by enzymatic assay, Isotope dilution mass spectroscopy&#xD;
                  [IDMS] standardized Jaffe assay, or non-IDMS Jaffe assay) &gt;1.5 times ULN or&#xD;
                  estimated glomerular filtration rate (eGFR) &lt;30mL/min/1.73m^2 (Chronic Kidney&#xD;
                  Disease Epidemiology [CKD-EPI] Collaboration equation); confirmation of eGFR is&#xD;
                  only required when creatinine is &gt;1.5 X ULN&#xD;
&#xD;
               -  International normalized ratio (INR) (only tested if clinically indicated) &gt;1.5&#xD;
                  times ULN (if treated with anticoagulants, prolonged INR is acceptable)&#xD;
&#xD;
          -  Any of the following cardiac criteria:&#xD;
&#xD;
               -  Mean resting corrected QT interval (QTc) &gt;470 msec&#xD;
&#xD;
               -  Any clinically important abnormalities (as assessed by the investigator) in&#xD;
                  rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle&#xD;
                  branch block, third degree heart block&#xD;
&#xD;
               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                  events such as heart failure, hypokalaemia, congenital long QT syndrome, family&#xD;
                  history of long QT syndrome or unexplained sudden death under 40 years-of-age, or&#xD;
                  any concomitant medication known to prolong the QT interval&#xD;
&#xD;
               -  Patients with an ejection fraction &lt;55% or the lower limit of normal of the&#xD;
                  institutional standard will be excluded. Only in cases where the Investigator (or&#xD;
                  the treating physician or both) suspects cardiac disease with negative effect on&#xD;
                  the EF, will the EF be measured during screening using an appropriate method&#xD;
                  according to local standards to confirm eligibility (e.g., echocardiogram [ECHO],&#xD;
                  multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than&#xD;
                  6 months prior to first administration of study drug can be accepted provided&#xD;
                  that there is clinical evidence that the EF value has not worsened since this&#xD;
                  measurement in the opinion of the Investigator or of the treating physician or&#xD;
                  both.&#xD;
&#xD;
          -  History of pneumonitis within the last 5 years&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other mAbs&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to the ingredients of study drug&#xD;
&#xD;
          -  Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within&#xD;
             4 weeks prior to the first dose of study treatment&#xD;
&#xD;
          -  Active autoimmune disease or a documented history of autoimmune disease, except&#xD;
             vitiligo or resolved childhood asthma/atopy, or asthma well controlled with steroids&#xD;
&#xD;
          -  Active infection requiring systemic treatment (antibacterial, antiviral, or antifungal&#xD;
             therapy) at start of treatment in this trial&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection or laboratory evidence&#xD;
             of hepatitis virus infection with positive results of hepatitis B surface (HBs)&#xD;
             antigen and/or presence of HBc antibody together with HBV-DNA and/or hepatitis C RNA&#xD;
             (HIV and hepatitis test results obtained in routine diagnostics are acceptable if done&#xD;
             within 14 days before the informed consent date). However, for patients with&#xD;
             hepatocellular cancer in Part III Cohorts C and D, patients with HBV and/or HCV&#xD;
             infection are allowed. Hepatocellular cancer patients in Part III Cohorts C and D with&#xD;
             HBV infection must be receiving effective antiviral therapy (viral load &lt;100 IU/mL)&#xD;
&#xD;
          -  Current or history of interstitial lung disease&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes him/her an unreliable trial patient, unlikely to complete the trial, or unable&#xD;
             to comply with the protocol procedures. However, for patients with hepatocellular&#xD;
             cancer in Part III Cohorts C and D, past chronic alcohol abuse are allowed&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant during the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba, Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama, Kitaadachi-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka, Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Foundation for Cancer Research</name>
      <address>
        <city>Tokyo, Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCKUH</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital(Linkou)</name>
      <address>
        <city>TaoYuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

